Publikationen in Zusammenarbeit mit Forschern von Hospital Universitari Germans Trias i Pujol (15)

2023

  1. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  2. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

  3. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 936-955

2022

  1. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  2. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  4. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials

    American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575

  5. Vericiguat in heart failure: from scientific evidence to clinical practice

    Revista Clinica Espanola

2021

  1. Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study

    Open Forum Infectious Diseases, Vol. 8, Núm. 6

  2. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival

    Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21

2020

  1. Intracoronary lithotripsy in a high-risk real-world population. First experience in severely calcified, complex coronary lesions

    REC: Interventional Cardiology, Vol. 2, Núm. 2, pp. 76-81

2018

  1. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial

    European Heart Journal, Vol. 39, Núm. 15, pp. 1255-1264

2013

  1. In-hospital and mid-term predictors of mortality after transcatheter aortic valve implantation: Data from the Tavi national registry 2010-2011

    Revista Espanola de Cardiologia, Vol. 66, Núm. 12, pp. 949-958

  2. Spironolactone in mild chronic heart failure: Insights from a propensity-matched analysis of the MUSIC study cohort

    International Journal of Cardiology, Vol. 168, Núm. 4, pp. 4525-4527

2005

  1. Contribución de la captura de híbridos de segunda generación del virus del papiloma humano en el cribado de afección cervical en mujeres con infección por el virus de la inmunodeficiencia humana

    Medicina Clinica, Vol. 125, Núm. 4, pp. 127-131